NOVARTIS

The mRNA therapeutics market is projected to grow from $33.5 billion in 2023 to $40.69 billion by 2028 at a CAGR of 4%, driven by factors like rising infectious diseases, personalized medicine demand, and regulatory support. Key trends include mRNA delivery tech advancements, saRNA platforms, and manufacturing scalability.

DelveInsight's report on Congestive Heart Failure Market (2020-2034) covers epidemiology, market trends, key companies, and therapies. Market size was ~USD 6,900 million in 2023, expected to grow significantly. Key companies include Novartis, Bayer, and Eli Lilly. Therapies like ENTRESTO and JARDIANCE are highlighted. Market drivers include aging population and disease prevalence, while barriers include generic therapies and diagnostic challenges.

Pfizer, Merck, and Eli Lilly & Co. contribute to one-third of pharma campaign donations. Kamala Harris received $1.12 million in donations, while Trump received $204,748. Both candidates aim to lower prescription drug prices, though the issue was only briefly discussed in a debate. Trump's efforts to lower prices faced industry and legislative resistance, while Harris' administration passed the Inflation Reduction Act, capping drug spending and negotiating lower prices for Medicare recipients. Harris' platform includes expanding drug cost caps to all insured Americans and protecting the Affordable Care Act, contrasting with Trump's opposition to the ACA and his vague healthcare plans. The pharmaceutical industry, aware of the risks, is hedging its bets by donating more to Democrats.

Pharmaust rebrands as Neurizon Therapeutics, focusing on neuro-degenerative diseases like ALS, using repurposed animal drug monepantel. The company plans a pivotal phase II/III trial with FDA fast-track approval potential, supported by a $900,000 grant from Fight MND.

Bloomberg connects decision makers to a dynamic network for global business and financial information, news, and insights.

Roche's SMA drug Evrysdi helped pre-symptomatic babies reach milestones in a Phase II trial, with all 26 children able to swallow and feed orally after two years, contrasting untreated Type 1 SMA. Cognitive development was comparable to non-SMA babies. Evrysdi, an oral SMN2 splicing modifier, was approved by the FDA in 2022 and generated CHF 1.4bn in 2023, with projections of $2.8bn by 2030, surpassing Biogen's Spinraza due to its oral delivery.

Roche's SMA drug Evrysdi helped pre-symptomatic babies reach milestones in a Phase II trial, with all 26 children able to swallow and feed orally without permanent ventilation after two years. Cognitive development was comparable to non-SMA babies. Evrysdi, an oral SMN2 splicing modifier, was approved by the FDA in 2022 and generated CHF 1.4bn in 2023, with projections of $2.8bn by 2030.

The global peptide therapeutics market is projected to grow from $42.1B in 2023 to $56.2B by 2030, driven by technological advancements, increasing demand for targeted treatments, and the rising incidence of chronic diseases. Peptide therapeutics offer high specificity and low toxicity, making them attractive for treating conditions like cancer and diabetes. Innovations in peptide engineering and delivery systems are enhancing their efficacy and stability, expanding their therapeutic potential across various diseases.

The FDA approved 55 new drugs last year, emphasizing the importance of selecting appropriate clinical outcome assessments (COAs) in drug development. COAs are crucial for collecting patient data and securing regulatory approval, ensuring outcomes are meaningful to patients. Effective COAs must be relevant, psychometrically sound, and meet regulatory standards. Poor COA selection risks misleading results, regulatory delays, and patient burden. Pearson assessments, used in successful drug development for conditions like schizophrenia and spinal muscular atrophy, highlight the integral role of well-validated COAs in advancing drug development and securing approval.

KEYNOTE-522 trial demonstrated significant overall survival benefit with pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer, with a 5-year survival rate of 86.6% vs 81.7% with chemotherapy alone.